This newsletter presents you the following key sessions:
1. Podcast with dr. Rodriguez-Abreu about pembrolizumab plus ipilimumab or placebo in previously untreated
metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: 3-year follow-up of Keynote-598
2. Clinical and molecular characteristics of long-term survivors in the CASPIAN trial
3. Savolitinib in the treatment of patients with non-small cell lung cancer and MET exon 14 skipping mutations
4. Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic
non-squamous NSCLC
5. Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutated lung adenocarcinoma